Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure

Abstract

Patients with early treatment failure after intensive first-line immunochemotherapy experience poor outcomes after receiving standard second-line immunochemotherapy. The use of standard-of-care or experimental therapies currently available in the third-line setting and beyond should be investigated in the second-line setting for these patients.